Search

MedMira’s

Innovation Roadmap

Driven by technology and guided by clinical needs, we advance rapid testing with purpose.
This roadmap outlines the developments shaping our next generation of solutions.

BUILT to ADVANCE

Rapid Testing Refined

Our development pipeline highlights key projects built on our two proprietary platforms, which enable versatile use across human health, food processing, and biosafety testing through both internal development and external partnerships.

Rapid Vertical Flow™ (RVF) Technology

Our patented RVF™ technology uses a rapid vertical flow design that shortens time-to-result and provides reliable, high-sensitivity signal detection, proven in validation studies and use across various settings.

Learn more
MiROQ™ System

Our emerging MiROQ™ platform combines RVF with SERS-based signal enhancement for quantitative liquid biopsy assays, tracking biomarker levels and trends over time – beyond simple yes/no results.

Learn more
From Innovation to Impact

What’s next in our pipeline

Our diagnostic pipeline illustrates the structured progression of tests from early development to regulatory submission. Each product follows a standardized pathway to ensure quality, performance, and regulatory compliance.

The pipeline is organized into five phases:

Phase 1 Product Development
Phase 2 Validation
Phase 3 Pre-Submission
Phase 4 Clinical Trials Phase
Phase 5 Final Submission

This phased structure provides a clear and transparent overview of the current status of each test within the pipeline.

Reveal® Breast Cancer Rapid Test
Target

Breast cancer–associated antigen

Biomarker class

Tumour-associated protein antigens

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Single

The Reveal® Breast Cancer Biomarker (CA 15.3) Antigen Rapid Test is developed for the monitoring of breast cancer–associated antigens.

Target

Breast Cancer

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Reveal® Multi-Cancer Monitoring Rapid Test
Target

Multiple cancer types (breast, pancreatic, ovarian, gastrointestinal, colorectal, lung, liver, germ cell tumours)

Biomarker class

Tumour-associated protein antigens 
(CA 27.29, CA 15-3, CA 19-9, CA 125, CEA, AFP)

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Single

Our oncology portfolio comprises rapid tests designed not only for breast cancer–associated markers but also for broader multi-cancer risk assessment. These tests identify panels of cancer-associated biomarkers to support early identification in clinical and research settings.

Target

Multiple cancer biomarkers

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Reveal® G4 CLIA (USA)
Target

HIV

Biomarker class

HIV-1 and HIV-2 antibodies

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Single

Enables qualitative detection of HIV-1 and HIV-2 antibodies across multiple specimen matrices. Designed for CLIA use in the U.S., it is currently in the final phase of clinical evaluation.

Target

HIV-1/2

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Reveal® Trich Antibody Test
Target

Trichomonas vaginalis

Biomarker class

Antibody against T. vaginalis antigens

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Single

The Reveal® Trichomoniasis Antibody Rapid Test is developed for the qualitative detection of Trichomonas vaginalis antibody in clinical blood specimens (finger-stick, venous blood, serum and plasma).

Target

Trichomoniasis

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Reveal® HSV-2
Target

Herpes simplex virus type 2 (HSV-2)

Biomarker class

Host-derived antibodies (IgG, IgM)

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Single

Our HSV-2 serology test focuses on type-specific IgG/IgM detection to help distinguish HSV-2 exposure from other herpesvirus responses. It is designed to support routine STI-related assessments in professional healthcare settings.

Target

HSV-2

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Multiplo® TP/nTP (Canada)
Target

Treponema pallidum (Syphilis)

Biomarker class

Treponemal (TP) and non-treponemal (nTP) antibodies

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Multiple

The Multiplo® Complete Syphilis (TP/nTP) Antibody Test is developed for the qualitative detection of Treponema pallidum (TP) and non-treponemal (nTP) antibodies in clinical whole blood specimens. Currently in the second phase of the clinical validation.

Target

Syphilis (TP)

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Multiplo® TP/HIV Self-Test
Target

HIV-1/2 and Treponema pallidum (Syphilis)

Biomarker class

Host-derived antibodies to HIV-1/2 and Treponema pallidum (TP)

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Multiple

Intended for the qualitative detection of HIV-1/2 and Treponema pallidum (TP) antibodies in a self-test format. Currently undergoing clinical validation.

Target

Syphilis (TP)

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Multiplo® STI NG/CT Rapid Test
Target

Neisseria gonorrhoeae (NG) / Chlamydia trachomatis (CT)

Biomarker class

Pathogen-derived bacterial protein antigens

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Multiple

Targets protein antigens specific to Neisseria gonorrhoeae and Chlamydia trachomatis for use in clinical testing environments. Development was supported by grant funding for NG and CT antigen detection.

Target

NG/CT

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Multiplo® TP/HIV/HCV Salvia Rapid Test
Target

Treponema pallidum (TP), Human Immunodeficiency Virus (HIV), 
Hepatitis C Virus (HCV)

Biomarker class

Pathogen-derived protein antigens and antibodies

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Multiple

Detects antigens associated with Treponema pallidum, HIV and HCV. Development was supported by grant funding, with validation conducted by the Johns Hopkins University Applied Physics Laboratory.

Target

TP/HIV/HCV

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Multilinx™ HBV
Target

Hepatitis B virus (HBV)

Biomarker class

Host-derived antibodies (anti-HBs, anti-HBc, anti-HBe) and viral antigens (HBsAg, HBcAg and HBeAg)

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Dual-mode testing

The Multilinx™ HBV Panel is designed to detect key hepatitis B markers, supporting evaluation of infection status and immunological response in clinical testing workflows.

Target

HBV

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Multilinx™ TP/HIV/HCV/HBsAg/HIV p24/HCV Core Rapid Test
Target

Treponema pallidum (TP), Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Hepatitis B Virus (HBV)

Biomarker class

Host-derived antibodies (TP Ab, HIV Ab, HCV Ab) and 
pathogen-derived viral antigens (HBsAg, HIV-1 p24 Ag, HCV core Ag)

Mechanism of detection

Vertical flow immunoassay (RVF technology™)

Test format

Dual-mode testing

Developed and validated by Qualtex, this rapid vertical flow assay is used under RUO conditions. The test enables the detection of antibodies and antigens associated with TP, HIV, HCV and HBV within a single multi-target test device.

Target

TP/HIV/HCV

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Phase 5
Privacy Policy

Last updated: April 20, 2026

MedMira Inc. (“MedMira”, “we”, “us”, or “our”) is committed to protecting personal information in accordance with applicable privacy laws, including the Personal Information Protection and Electronic Documents Act (PIPEDA) in Canada, as well as applicable United States and international privacy requirements.

This Privacy Policy describes how we collect, use, disclose, and safeguard personal information through our website. Our website is primarily informational in nature and does not provide user accounts, applications, or diagnostic services.

1. Personal Information We Collect

We collect personal information only where it is voluntarily provided by you. “Personal information” means information about an identifiable individual. The types of personal information we may collect include:

a) Contact Forms
When you submit an inquiry, we may collect your first and last name, email address, phone number (optional), organization (optional), inquiry details, selected topic, and message, as well as your self-identified category (e.g., partner, healthcare provider, researcher, investor, media, or other).

b) Newsletter Subscription
If you subscribe to receive updates, we may collect your email address and, where provided, your category or area of interest.

c) Communications
We may retain records of communications you send to us, including emails and inquiries, in order to respond to you and maintain appropriate business records.

We collect personal information directly from you and do not knowingly obtain personal information from data brokers or unrelated third-party sources.

If you provide personal information relating to another individual, you represent that you have the authority to do so and that such information may be used in accordance with this Privacy Policy.

We do not intentionally collect sensitive personal information or collect more information than necessary for the purposes described herein.

2. Purposes of Collection and Use

MedMira collects and uses personal information for limited and legitimate business purposes, including responding to inquiries, communicating with you, providing information about our company and activities, delivering newsletters or updates where you have opted in, maintaining internal records, and complying with applicable legal and regulatory obligations.

We do not use personal information for profiling, automated decision-making, or targeted advertising.

3. Consent

By submitting personal information to MedMira, you consent to its collection, use, and disclosure as described in this Privacy Policy.

Where required by applicable law, you may withdraw your consent at any time, subject to legal or contractual restrictions and reasonable notice. Withdrawal of consent may limit our ability to respond to your inquiry or provide requested information.

4. Cookies and Similar Technologies

MedMira’s website does not use cookies, analytics tools, or tracking technologies for advertising or behavioral tracking purposes.

However, our website may include content or links to third-party platforms, such as LinkedIn, X (formerly Twitter), or YouTube. Interaction with such content (including embedded media or external links) may result in those third parties placing cookies or using similar technologies on your device.

MedMira does not control and has no access to data collected through such third-party technologies.

5. Disclosure of Personal Information

MedMira does not sell, rent, or trade personal information.

We may disclose personal information to third parties only in limited circumstances, including to service providers acting on our behalf (such as email distribution providers), who are contractually required to protect the information and use it only for the intended purposes.

We may also disclose personal information where required by law, regulation, legal process, or to protect the rights, property, or safety of MedMira or others, or in connection with a corporate transaction where permitted by law.

6. Third-Party Websites and External Services

Our website may contain links to or integrations with third-party services, including but not limited to Google Maps, SEDAR (System for Electronic Document Analysis and Retrieval), PubMed, LinkedIn, X (formerly Twitter), and YouTube.

These services are operated by independent third parties. When you access or interact with such services, your personal information may be collected and processed directly by those third parties in accordance with their own privacy policies.

MedMira does not control and assumes no responsibility or liability for the privacy practices, content, or data handling activities of third-party services. Accessing such services is at your own risk.

7. Data Retention

We retain personal information only for as long as necessary to fulfill the purposes for which it was collected, including responding to inquiries, maintaining communication records, and providing newsletters.

Personal information associated with newsletter subscriptions is retained until you unsubscribe. We may retain information for longer periods where required to comply with legal obligations or to establish, exercise, or defend legal claims.

8. Safeguards and Security

MedMira implements reasonable administrative, technical, and organizational safeguards appropriate to the sensitivity of the information to protect personal data against loss, theft, unauthorized access, disclosure, copying, use, or modification.

However, no method of transmission over the Internet or electronic storage is completely secure. While we take appropriate steps to protect personal information, we cannot guarantee absolute security, and any transmission of information is at your own risk.

9. Cross-Border Transfers

MedMira is headquartered in Canada but may engage service providers located in other jurisdictions, including the United States. As a result, personal information may be transferred to and processed in jurisdictions outside your country of residence.

Such jurisdictions may have different data protection laws and may permit access by governmental authorities under applicable laws. By providing your personal information, you consent to such transfers where permitted by law.

10. Your Rights and Choices

Subject to applicable law, you may have the right to access, correct, or request deletion of your personal information, withdraw your consent to processing, or opt out of receiving communications.

To exercise your rights, please contact us using the contact details below. We will respond to requests in accordance with applicable legal requirements.

11. Children’s Privacy

Our website is accessible to individuals of all ages but is not specifically directed at children. We do not knowingly collect personal information from children without appropriate consent.

If you believe that a child has provided personal information to us, please contact us so that we can take appropriate steps to remove such information where required.

12. Limitation of Liability

To the fullest extent permitted by applicable law, MedMira disclaims liability for the privacy practices, actions, or omissions of third parties, including external websites and service providers not under our direct control.

13. Changes to This Privacy Policy

MedMira reserves the right to update or modify this Privacy Policy at any time. Any changes will be posted on this page with a revised “Last updated” date. Continued use of the website following such changes constitutes acceptance of the updated Privacy Policy.

14. Contact Information

For questions, requests, or concerns regarding this Privacy Policy or our data practices, please contact:

MedMira Inc.
155 Chain Lake Drive, Suite 1
Halifax, Nova Scotia B3S 1B3
Canada

Email: info@medmira.com
Phone: +1 (902) 450 1588
Toll Free: +1 (877) 633 6372

Terms And Conditions Of Use

Please Read These Terms Carefully Before Using This Site. This website is provided by MedMira Inc. (MedMira) and may be used for informational purposes only. By using the site or downloading materials from the site, you agree to abide by the terms and conditions set forth in this notice. If you do not agree to abide by these terms and conditions do not use the site or download materials from the site.

Limited License

Subject to the terms and conditions set forth in this Agreement, MedMira grants you a non-exclusive, non-transferable, limited right to access, use and display this site and the materials thereon. You agree not to interrupt or attempt to interrupt the operation of the site in any way. MedMira authorizes you to view and download the information (“Materials”) at this website (“Site”) only for your personal, non-commercial use. This authorization is not a transfer of title in the Materials and copies of the Materials and is subject to the following restrictions: 1) you must retain, on all copies of the Materials downloaded, all copyright and other proprietary notices contained in the Materials; 2) you may not modify the Materials in any way or reproduce or publicly display, perform, or distribute or otherwise use them for any public or commercial purpose; and 3) you must not transfer the Materials to any other person unless you give them notice of, and they agree to accept, the obligations arising under these terms and conditions of use. You agree to abide by all additional restrictions displayed on the Site as it may be updated from time to time. This Site, including all Materials, is copyrighted and protected by worldwide copyright laws and treaty provisions. You agree to comply with all copyright laws worldwide in your use of this Site and to prevent any unauthorized copying of the Materials. Except as expressly provided herein, MedMira does not grant any express or implied right to you under any patents, trademarks, copyrights or trade secret information.

Website Disclaimer

THE MATERIALS MAY CONTAIN INACCURACIES AND TYPOGRAPHICAL ERRORS. MEDMIRA DOES NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE MATERIALS OR THE RELIABILITY OF ANY ADVICE, OPINION, STATEMENT OR OTHER INFORMATION DISPLAYED OR DISTRIBUTED THROUGH THE SITE. YOU ACKNOWLEDGE THAT ANY RELIANCE ON ANY SUCH OPINION, ADVICE, STATEMENT, MEMORANDUM OR INFORMATION IS AT YOUR SOLE RISK.
MEDMIRA RESERVES THE RIGHT, IN ITS SOLE DISCRETION, TO CORRECT ANY ERRORS OR OMISSIONS IN ANY PORTION OF THE SITE WITHOUT NOTICE. MEDMIRA MAY MAKE ANY OTHER CHANGES TO THE SITE, THE MATERIALS AND THE PRODUCTS PROGRAMS, SERVICES OR PRICES (IF ANY) DESCRIBED IN THE SITE AT ANY TIME WITHOUT NOTICE.
THIS SITE, THE INFORMATION AND MATERIALS ON THE SITE, AND ANY SOFTWARE MADE AVAILABLE ON THE SITE, ARE PROVIDED “AS IS, WHERE IS, AS AVAILABLE” WITHOUT ANY REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, OF ANY KIND, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT, OR FITNESS FOR ANY PARTICULAR PURPOSE. YOU EXPRESSLY ACKNOWLEDGE THAT THERE ARE NO WARRANTIES OR REPRESENTATIONS MADE REGARDING THE CONTENT OF ANY PORTION OF THE SITE INCLUDING WITHOUT LIMITATION HOW CURRENT IT IS, ITS ACCURACY, ITS COMPLETENESS, ITS AVAILABILITY, ITS SECURITY, THAT DEFECTS WILL BE CORRECTED OR THAT THE SITE, ANY HYPERLINKED WEBSITE, OR THE SERVERS UPON WHICH THEY RESIDE ARE FREE OF VIRUSES OR OTHER HARMFUL COMPONENTS. SOME JURISDICTIONS DO NOT ALLOW FOR THE EXCLUSION OF IMPLIED WARRANTIES, SO SOME OF THE ABOVE EXCLUSIONS MAY NOT APPLY TO YOU.
The information in this Site does not constitute medical or other advice and is not intended to be a substitute for advice given by a physician or other qualified healthcare professional or specialist. Always seek the advice of a physician or other qualified healthcare professional with any health questions you may have. If you would like more information or further guidance, you are encouraged to speak to your doctor.
Some background, abstract, or decorative images on this website were created or enhanced using AI technology. These visuals are artistic interpretations and may not fully or accurately represent real-world details. Users are encouraged to verify important details, as AI-generated imagery may contain inaccuracies. By using this site, you acknowledge and agree to these terms regarding AI-generated content.

Third Party Sites

As a convenience to you, MedMira may provide, on this Site, links to websites operated by other entities. If you use these sites, you will leave this Site. If you decide to visit any linked site, you do so at your own risk and it is your responsibility to take all protective measures to guard against viruses or other destructive elements. MedMira makes no warranty or representation regarding, and does not endorse, any linked Web sites or the information appearing thereon or any of the products or services described thereon. Links do not imply that MedMira or this Site sponsors, endorses, is affiliated or associated with, or is legally authorized to use any trademark, trade name, logo or copyright symbol displayed in or accessible through the links, or that any linked site is authorized to use any trademark, trade name, logo or copyright symbol of MedMira or any of its affiliates or subsidiaries.

External Links to the Site

All links to the Site must be approved in writing by MedMira, except that MedMira consents to links in which: (i) the link is a text-only link containing only the name “MedMira“; (ii) the link “points” only to www.medmira.com and not to deeper pages;(iii) the link, when activated by a user, displays that page full-screen in a fully operable and navigable browser window and not within a “frame” on the linked website; and (iv) the appearance, position and other aspects of the link may neither create the false appearance that an entity or its activities or products are associated with or sponsored by MedMira nor be such as to damage or dilute the goodwill associated with the name and trademarks of MedMira or its Affiliates. MedMira reserves the right to revoke this consent to link at any time in its sole discretion.

Limitations of Damages

YOU EXPRESSLY AGREE THAT USE OF THE SITE IS AT YOUR SOLE RISK. NONE OF MEDMIRA NOR ANY OF ITS RESPECTIVE DIRECTORS, EMPLOYEES, AGENTS OR OTHER REPRESENTATIVES WILL BE LIABLE FOR DAMAGES, CLAIMS, EXPENSES OR OTHER COSTS (INCLUDING WITHOUT LIMITATION LEGAL FEES) ARISING OUT OF OR IN CONNECTION WITH THE USE OF, OR INABILITY TO USE, THE SITE OR ANY INFORMATION CONTAINED ON IT, OR ANY HYPERLINKED WEBSITE, WHETHER CLAIMED IN CONTRACT, NEGLIGENCE OR ANY OTHER CAUSE OF ACTION. THIS IS A COMPREHENSIVE LIMITATION OF LIABILITY THAT APPLIES TO ALL DAMAGES OF ANY KIND, INCLUDING (WITHOUT LIMITATION) COMPENSATORY, DIRECT, INDIRECT, EXEMPLARY, PUNITIVE AND CONSEQUENTIAL DAMAGES, PERSONAL INJURY, LOSS OF PROGRAMS OR DATA, INCOME OR PROFIT, LOSS OR DAMAGE TO PROPERTY AND CLAIMS OF THIRD PARTIES.

Changes

MedMira reserves the right, at its sole discretion, to change, modify, add or remove any portion of this Agreement in whole or in part, at any time. Changes in this Agreement will be effective when notice of such change is posted. Your continued use of the Site after any changes to this Agreement are posted will be considered acceptance of those changes. MedMira may terminate, change, suspend or discontinue any aspect of the MedMira Site, including the availability of any features of the Site, at any time. MedMira may also impose limits on certain features and services or restrict your access to parts or all of the Site without notice or liability. MedMira may terminate the authorization, rights and license given above and, upon such termination, you shall immediately destroy all Materials.

Subscribe
Join our newsletter

Receive company updates, regulatory milestones, and event announcements.

By subscribing, you agree to our Privacy Policy and consent to receive updates.

Committed to quality
Certified & Proven Quality

Our quality management system is ISO 13485:2016 certified, compliant with the United States Food and Drug Administration’s current Good Manufacturing Practices (cGMP: Quality System Regulation Part 820 of CFR Title 21, Volume 8), European Union’s Directive 98/79/EC on in vitro diagnostic medical devices, and Health Canada Medical Device Regulations (SOR/98-282).

Additionally, we adhere to ISO 14971 (Application of Risk Management to Medical Devices) and ISO 2859 (Sampling Procedures for Inspection by Attributes). Certification and compliance to these requirements attests to our ability to maintain the highest standard of quality in medical device manufacturing, product development and corporate conduct.

Our products have been approved by regulators and UN agencies worldwide.

FDA

Health Canada

International Trade Centre (ITC)

Pan American Healtch Organization (PAHO)

UN Development Programme (UNDP)

UN Office for Project Services (UNOPS)

UN Office at Vienna (UNOV)

UN Population Fund (UNFPA)

United States Agency for International Development (USAID)

CFO & Head of Commercialization

Markus Meile

Markus joined MedMira in 2010, and moved into the role of Chief Financial Officer in 2014.

He previously served on the Company’s Board of Directors, as a member of the Audit Committee, and as the Senior Director of International Markets.

Prior to joining MedMira, Markus worked with a number of financial institutions in Switzerland, England, and Hong Kong. He holds a BSc from Royal Holloway University of London and has studied business management, strategic planning, investment and accounting at business school in Zurich. Previously, Markus worked in the medical device industry in Africa, Asia Pacific, and Europe.

He will combine his financial expertise with his broad range of international business knowledge to build financial and corporate strategies supporting MedMira’s continuing growth and increasing shareholder value.

Director of the Audit Committee, Nomination and Compensation Committee

Jianhe Mao

Jianhe Mao is the owner of Unipec, a consulting firm based in St. Gallen, Switzerland. Unipec focuses on helping European companies enter the Chinese market, through operational restructuring and ownership and management optimization.

In addition to leading Unipec, Mr. Mao is involved in several industrial projects and start-up ventures including Monsatec AG, a new company bridging the gap between laboratories and clinics with a cold plasma medical device. He serves on the boards of several European companies and is regarded as a trusted expert in legal cases, corporate corruption, operational turnarounds, and mergers and acquisitions.

Mr. Mao began his career as a project engineer and has gained experience in business development and real estate investment. He holds M.E. from Ruhr University Bochum.

CEO, Co-Founder & Co-Inventor

Hermes Chan, D.Sc. (h.c.)

Hermes Chan, our Chief Executive Officer and Co-Founder, leads our passionate and committed team in driving the strategic direction and growth of MedMira.

Hermes, who was named BioScience Innovator of the Year by The Economist in 2007, is the inventor of our patented rapid flow-through diagnostic technology platform.

Since the company’s inception in 1994 Hermes has held progressively senior management roles including Research Scientist, General Manager, Senior Vice President, and Chief Operating Officer.

Prior to creating MedMira, Hermes worked with another Canadian biotechnology company in the diagnostics research sector.

Chair member of the Audit Committee, Nomination and Compensation Committee

Steven Cummings

Mr. Steven Cummings is the Founder & President of Cambridge Financial Services, one of the leading full service accounting, tax, and business advisory firms in Nova Scotia.

Under Mr. Cummings leadership, Cambridge Financial has earned an enviable reputation among businesses and industry for a commitment to high standards. Along with his leadership responsibilities at Cambridge Financial Services, Mr. Cummings was engaged as MedMira’s interim Chief Financial Officer in 2007.

With more than 30 years of financial and entrepreneurial experience, Mr. Cummings is a frequent guest speaker on issues surrounding provincial taxation, taxation of seniors, and business ownership

Intellectual property

China

ZL02819646.5

Rapid Diagnostic Device and Assay

Intellectual property

European union

EP1417489

Rapid Diagnostic Device and Assay

EP1328811

HCV Mosaic Antigen Composition (2021)

Intellectual property

USA

9,164,087

Rapid Diagnostic Device, assay and multifunctional Buffer

9,086,410

Downward or vertical flow diagnostic device and assay

8,025,850

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,287,817

Rapid Diagnostic Device, Assay and Multifunctional Buffer

8,586,375

Rapid Diagnostic Device, Assay and Multifunctional Buffer

7,531,362

Rapid Diagnostic Device, Assay and Multifunctional Buffer

D706945

Diagnostic Device

D706466

Diagnostic Device

11,353,450

Analyte Detection Using Raman Spectroscopy

Intellectual property

Canada

CA2,493,616

Rapid Diagnostic Device, Assay and Multifunctional Buffer

CA2,740,902

Downward or Vertical Flow Diagnostic Device and Assay

CA2,949,634

Analyte Detection Using Raman Spectroscopy

MiROQ Vision

Handheld Device

A future concept built on the same MIROQ technology, designed to deliver lab-grade precision in the palm of your hand.

We envision a future where testing can happen anywhere, anytime – from hospitals and clinics to remote regions or even at home – enabling early disease detection and turning knowledge into real impact. No large equipment or complex infrastructure required.

For: Doctor’s offices, small and mobile clinics

Future application: Home use

Connectivity: Bluetooth, Wifi and USB